Effectiveness of Corticosteroids on Persistent Inflammation,Immunosuppression,and Catabolism Syndrome in Patients with Septic Shock: A Retrospective Claims Database Study

Abstract

Background

Persistent inflammation, immunosuppression, and catabolism syndrome (PICS) that develops following critical illness is one of the most challenging issues in critical care medicine. While corticosteroids are widely used in septic shock, their impact on PICS remains unclear. While corticosteroids may reduce inflammation, they potentially increase infection risk and affect muscle function.

Methods

This retrospective cohort study analyzed 3186 patients with septic shock from a Japanese administrative claims database, which was supplied by Medical Data Vision Co., Ltd (Tokyo, Japan). Using propensity score matching, we compared outcomes between patients who received corticosteroids within the first two days of admission (steroid group) and those who did not (control group). The primary outcome was the incidence of PICS on day 28, defined as meeting at least two of the following criteria: C-reactive protein >2.0 mg/dL, albumin <3.0 g/dL, and lymphocyte count <800/μL.

Results

A total of 4054 patients were enrolled in this retrospective cohort study. After the exclusion of 868 patients, 3186 eligible patients (906 in the steroid group and 2280 in the control group) were included in the propensity score analysis. After matching, there was no significant difference in the incidence of PICS on day 28 between the steroid and control groups (16.7% vs 13.6%; risk difference, 2.22%; 95% CI, −1.89% to 6.34%; P = 0.095). Additionally, no significant differences were observed in 28-day mortality (15.2% vs 15.2%), in-hospital mortality, PICS on day 14, the Barthel Index at discharge or the percentage of patients meeting PICS criteria for each component on day 14 and day 28.

Conclusions

The administration of corticosteroids in patients with septic shock was not associated with the incidence of PICS.

Keywords

corticosteroids sepsis persistent inflammation immunosuppression and catabolism syndrome

Get full access to this article

View all access options for this article.

References

Gentile

Cuenca

Efron

, et al. Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012;72(6):1491-1501. doi:https://doi.org/10.1097/TA.0b013e318256e000

Mira

Gentile

Mathias

, et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit Care Med. 2017;45(2):253-262. doi:https://doi.org/10.1097/CCM.0000000000002074

Nakamura

Ogura

Nakano

, et al. Disseminated intravascular coagulopathy is associated with the outcome of persistent inflammation, immunosuppression and catabolism syndrome. J Clin Med. 2020;9(8):2662. doi:https://doi.org/10.3390/jcm9082662

Efron

Mohr

Bihorac

, et al. Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery. Surgery. 2018;164(2):178-184. doi:https://doi.org/10.1016/j.surg.2018.04.011

Steinhagen

Schmidt

Schewe

Peukert

Klinman

Bode

. Immunotherapy in sepsis - brake or accelerate? Pharmacol Ther. 2020;208(107476):107476. doi:https://doi.org/10.1016/j.pharmthera.2020.107476

Cain

Cidlowski

. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233-247. doi:https://doi.org/10.1038/nri.2017.1

Hawkins

Raymond

Stortz

, et al. Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome. Front Immunol. 2018;9:1511. doi:https://doi.org/10.3389/fimmu.2018.01511

Nakamura

Ogura

Nakano

, et al. C-reactive protein clustering to clarify persistent inflammation, immunosuppression and catabolism syndrome. Intensive Care Med. 2020;46(3):437-443. doi:https://doi.org/10.1007/s00134-019-05851-3

Annane

Bellissant

Bollaert

, et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev. 2019;12(12):CD002243. doi: https://doi.org/10.1002/14651858.CD002243.pub4

10.

Zhang

Luo

Miao

Zhong

. Hypercatabolism and anti-catabolic therapies in the persistent inflammation, immunosuppression, and catabolism syndrome. Front Nutr. 2022;9:941097. doi: https://doi.org/10.3389/fnut.2022.941097

11.

Tuttle

CSL

Thang

LAN

Maier

. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis. Ageing Res Rev. 2020;64(101185):101185. doi:https://doi.org/10.1016/j.arr.2020.101185

12.

Venkatesh

Finfer

Cohen

, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797-808. doi:https://doi.org/10.1056/NEJMoa1705835

13.

Liang

Song

Zhai

, et al. Corticosteroids for treating sepsis in adult patients: A systematic review and meta-analysis. Front Immunol. 2021;12:709155. doi:https://doi.org/10.3389/fimmu.2021.709155

14.

Evans

Rhodes

Alhazzani

, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181-1247. doi:https://doi.org/10.1007/s00134-021-06506-y

15.

Cecconi

Evans

Levy

Rhodes

. Sepsis and septic shock. Lancet. 2018;392(10141):75-87. doi:https://doi.org/10.1016/S0140-6736(18)30696-2

16.

Venkatesh

Cohen

. Hydrocortisone in vasodilatory shock. Crit Care Clin. 2019;35(2):263-275. doi: https://doi.org/10.1016/j.ccc.2018.11.005

17.

Wang

, et al. Immunotherapy in the context of sepsis-induced immunological dysregulation. Front Immunol. 2024;15:1391395. doi: https://doi.org/10.3389/fimmu.2024.1391395

18.

Torres

Pickkers

van der Poll

. Sepsis-Induced immunosuppression. Annu Rev Physiol. 2022;84:157-181. doi: https://doi.org/10.1146/annurev-physiol-061121-040214

19.

Liu

Huang

Sun

, et al. Sepsis-induced immunosuppression: Mechanisms, diagnosis and current treatment options. Mil Med Res. 2022;9(1):56. doi: https://doi.org/10.1186/s40779-022-00422-y

20.

Wang

Zhou

. Persistent inflammation-immunosuppression-catabolism syndrome in patients with systemic lupus erythematosus. Int Urol Nephrol. 2023;55(7):1757-1765. doi: https://doi.org/10.1007/s11255-023-03479-3

21.

Yasunaga

. Real world data in Japan: Chapter II the diagnosis procedure combination database. Ann Clin Epidemiol. 2019;1(3):76-79. doi: https://doi.org/10.37737/ace.1.3_76

22.

Tonai

Shiraishi

Karumai

, et al. Hospital-onset sepsis and community-onset sepsis in critical care units in Japan: A retrospective cohort study based on a Japanese administrative claims database. Crit Care. 2022;26(1):136. doi:https://doi.org/10.1186/s13054-022-04013-0

23.

Quan

Couris

, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682. doi:https://doi.org/10.1093/aje/kwq433

24.

Khanna

English

Wang

, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419-430. doi:https://doi.org/10.1056/NEJMoa1704154

25.

Nakamura

Ogura

Ohbe

Goto

. Clinical criteria for persistent inflammation, immunosuppression, and catabolism syndrome: An exploratory analysis of optimal cut-off values for biomarkers. J Clin Med Res. 2022;11(19):5790. doi:https://doi.org/10.3390/jcm11195790

26.

Schweickert

Pohlman

, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: A randomised controlled trial. Lancet. 2009;373(9678):1874-1882. doi:https://doi.org/10.1016/S0140-6736(09)60658-9

27.

Griswold

Localio

Mulrow

. Propensity score adjustment with multilevel data: Setting your sites on decreasing selection bias. Ann Intern Med. 2010;152(6):393-395. doi:https://doi.org/10.7326/0003-4819-152-6-201003160-00010

28.

Rosenbaum

Rubin

. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33-38. doi:https://doi.org/10.1080/00031305.1985.10479383

29.

Heming

Sivanandamoorthy

Meng

Bounab

Annane

. Immune effects of corticosteroids in sepsis. Front Immunol. 2018;9:1736. doi:https://doi.org/10.3389/fimmu.2018.01736

30.

de Kruif

Lemaire

Giebelen

, et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol. 2007;178(3):1845-1851. doi:https://doi.org/10.4049/jimmunol.178.3.1845

31.

Briegel

Jochum

Gippner-Steppert

Thiel

. Immunomodulation in septic shock: Hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol. 2001;12(Suppl 17):S70-S74.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB